DCRT vs. Surgery in Resectable ESCC Patient Achiving cCR/PR After nCI

This is a multi-center, Phase II clinical study aiming to evaluate the efficacy, safety, and organ preservation feasibility of definitive concurrent chemoradiotherapy versus surgery in patients with locally advanced resectable esophageal squamous cell carcinoma (ESCC) who achieve clinical complete response/partial response (cCR/PR) after neoadjuvant chemo-immunotherapy. A total of 120 eligible subjects will be enrolled. Patients with cCR/PR after 2-3 cycles of neoadjuvant chemo-immunotherapy will be grouped based on personal willing: the control group (n=60) will receive radical esophagectomy + mediastinal lymph node dissection; the experimental group (n=60) will receive definitive concurrent chemoradiotherapy (radiotherapy: 50.4 Gy/28f; chemotherapy: nab-paclitaxel 175mg/m² + carboplatin AUC=5, q21d for 2 cycles). All the patients will receive camrelizumab maintenance therapy (200mg q21d) up to 1 year.

NCT Number	NCT07162506
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital Collaborators: Shanxi Province Cancer Hospital, Sichuan Province Cancer Hospital, Henan Province Cancer Hospital
Conditions	Esophageal Cancer
Enrollment	120 participants
Start Date	2025-11-03
Primary Completion	2027-08-30 (estimated)
Study Completion	2030-08-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-29